Bivamelagon
Phase 2Small molecule
Rhythm PharmaceuticalsBivamelagon is one of 7 small molecule programs targeting Hypothalamic Obesity. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Hypothalamic Obesity
#DrugCompanyPhaseTrials
1Sandostatin
Sun PharmaApproved
Corlanor
AmgenPhase 3
Imcivree
Rhythm PharmaceuticalsPhase 3
Inderal
WWyeth-Lederle Vaccines
Phase 3
Sandostatin LAR
NovartisApproved
Adipex-P
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Bivamelagon
Rhythm PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bivamelagon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company